



O'ZBEKISTON RESPUBLIKASI
SOG'LIQNI SAQLASH VAZIRLIGI

TOSHKENT TIBBIYOT AKADEMIYASI



**«ICHKI KASALLIKLARNI DIAGNOSTIKASI
VA DAVOLASHNING DOLZARB MUAMMOLARI»
XALQARO ILMYI-AMALIY ANJUMANI
TEZISLAR TO'PLAMI**

2022 yil 17 may

**СБОРНИК ТЕЗИСОВ МЕЖДУНАРОДНОЙ
НАУЧНО-ПРАКТИЧЕСКОЙ КОНФЕРЕНЦИИ
«АКТУАЛЬНЫЕ ПРОБЛЕМЫ ДИАГНОСТИКИ
И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
ВНУТРЕННИХ ОРГАНОВ»**

17 мая 2022 г.

EFFECT OF REBAGIT ON GASTRIC MUCOSA IN PATIENTS WITH NSAID GASTROPATHY

MUSAEVA L.J., AKBAROVA D.S., PULATOVA N.I., SAIFIEVA N.H.

Tashkent Medical Academy, Tashkent, Uzbekistan

Objective of the study. To study the effect of rebagit on gastric mucosa in patients with NSAID gastropathies.

Materials and methods. The study involved 72 patients aged 20–65 years. Patients of the first group –35 patients received antisecretory therapy: pantoprazole 40 mg x 1 time daily during 14 days. Patients of the second group –37 people, against the background of pantoprazole 40 mg x once a day for 14 days received rebagit 100 mg 3 times a day. The criteria for selection to both groups were the presence of erosive changes of gastric mucosa and fresh ulcers on endoscopic examination.

Results. The conducted research showed that patients in both groups had erosive lesions of the gastric antral mucosa according to endoscopic examination. In both groups multiple erosions and ulcers with sizes from 1 to 3 mm prevailed. Average sizes of ulcerous defects in the second

group were $1,75 \pm 0,75$ mm, in the comparison group – $1,69 \pm 0,57$ mm. After 14 days course of combined therapy (II group of patients) healing of ulcerous defects was found in 33 patients out of 37 (89,1%). In the remaining 4 patients there were marked positive endoscopic dynamics in the form of reduction of ulcer size by 2–3 times. At control esophagogastroduodenoscopy in patients of group I in 14 days from the start of treatment, complete epithelialization of erosions occurred only in 2 patients out of 35 monitored (60,2%). In 10 patients (25,8%) reduction of ulcer size in 2–3 times (on the average up to $1,4 \pm 0,6$ mm) was noted.

Conclusions: Thus, our observations demonstrate a significant reparative effect of combination therapy in the group with rebagit: epithelialization of erosion within 14 days of treatment was observed in 89,1% of patients. Our studies suggest that rebagit is an effective drug for treatment of NSAID gastropathy.

IMPACTS OF SYSTEMIC SCLEROSIS ON THE INTESTINAL TRACT AND LARGE INTESTINE OBSTRUCTION

PO'LATOVA N. O., ABDURAZZAKOVA D.S.

Tashkent Medical Academy, Tashkent, Uzbekistan

The aim of research. The systemic manifestations of systemic sclerosis (SSc, scleroderma) are diverse. Most prominent are abnormalities of the circulation (most notably Raynaud phenomenon) and involvement of multiple organ systems, including the musculoskeletal, renal, pulmonary, cardiac, and gastrointestinal (GI) systems, with fibrotic and vascular complications. Gastrointestinal symptoms can cause significant morbidity. The most damaged gastrointestinal organ is oesophagus, affecting 70–90%, the second is stomach, the third degree damaged GI organ bowels. The bowels are the third most commonly affected organ in SSc. In systemic scleroderma, the same process as in the skin is observed in the internal organs (heart, gastrointestinal tract, kidneys). Microcirculation is disrupted and generalized fibrosis develops. The aim of research is to assess the resulting bowel obstruction and strive preventive measures bowel obstruction due to systemic scleroderma.

Materials and methods. A 58-year-old female with systemic scleroderma presented with abdominal pain, constipation, loss of appetite, swelling of the abdomen, vomiting and can't pass gas. This patient had been suffering from systemic scleroderma since the age of 34 years. Scleroderma with giant diverticula of the colon produced the signs and symptoms of

obstruction have been presented. In radiographia have been emerged diverticula and obstruction in sigmoid colon. Thinning and weakening of the muscle wall can lead to formation of large diverticuli. The patient has been treated surgically.

Result. We believe the obstruction in our patient was a result of multifactorial manifestations of her systemic disease. Scleroderma patients and their physicians should be aware of the possibility of colonic obstruction, as aggressive medical and surgical management may be needed to avoid significant morbidity and even mortality.

Conclusion. Colonic obstruction may occur in 0,3% patients with systemic scleroderma. In 90% of cases, obstruction in such patients is caused by colonic diverticula. In 10% of cases, due to chronic constipation or diarrhea, the intestinal wall weakens and obstruction develops over years in SSc. The 58-year-old female patient had been suffering from systemic scleroderma for 24 years. In scleroderma there is a weakening of the gut muscles and impaired motility. This can lead to constipation. Diverticula formation is also caused by the constant intake of nonsteroidal anti-inflammatory drugs due to SSc. A patient over the age of 50 may also be the cause of diverticula. Over time, the inflammation can lead to bowel obstruction, which may cause constipation, the

stools, diarrhea, bloating and belly pain. In summary, systemic scleroderma is a very rare disorder that can frequently affect the gut. When early in its course, some people with scleroderma can be misdiagnosed

as having a functional GI disorder, such as IBS, functional constipation, or functional bloating, among other conditions.

THERAPEUTIC EFFECTS OF GLUTATHIONE ON DIABETIC NEUROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS

¹SHAGAZATOVA B.KH, ¹ARTIKOVA D.M, ²ARTIKOVA SH.A.

¹ Tashkent Medical Academy, ² Tashkent pediatric medical institute, Tashkent, Uzbekistan

Purpose. To evaluate the effects of glutathione on regression of diabetic neuropathy in patients with diabetes mellitus type 2 (T2DM).

Materials and Methods. A total of 83 T2DM patients (58 women and 25 men), who were given glutathione (Neomarin, China) for 10 days and a control group of 15 patients (10 women and 5 men) were evaluated in this study. All patients had the history of T2DM more than 10 years and the history of diabetic neuropathy more than 5 years. Participants in the experiment group had the average age of 48.2 ± 2.1 years, FPG (fasting plasma glucose) 9.7 ± 2.97 mmol/l and HbA1c between 7.8–10.31%. The participants of the control group had the average age of 54.1 ± 1.8 years and HbA1c between $7.7 \pm 0.5\%$. Hypoglycemic therapy was ordered to all patients in the experimental group (43%-insulin therapy and 57%-oral hypoglycemic drugs) while the control group received basic therapy (hypoglycemic therapy and hemodynamic stabilization.) Glutathione 1200 mg (Neomarin, China) was given for diabetic neuropathy to the patients in the experimental group for 10 days. Neurological examination was performed using TSS (Total Symptom Score), NSS (Neurological Symptoms Score), NDS (Neuropathy Disability Score) and VAS (visual analog scale).

Results. The study lasted for 10 days. Pain intensity was measured by using VAS. In the experimental group the VAS result was 6.42 ± 1.8 sm. Neurologic complaints significantly decreased 1/3 of the patients in the experimental group during first week of glutathione treatment. While pain was preserved in this time, it was mild and 5.2 ± 0.4 sm by VAS. The frequency of neuropathy symptoms (pain, numbness, paresthesia and burning sensation) was much lower in the experimental group than the control group. A number of scores in TSS lowered by 28% and 15.7% in the experimental group and in the control group respectively. Neurological symptoms by NDS scale reduced by 28.6%, from 26.5 score to 19.5 score ($p \leq 0.05$) in the group of patients receiving glutathione while the same symptoms by NDS scale lowered from 24.2 score to 20.1 score in the control group.

Conclusion. 1. Using glutathione helped to reduce the frequency of neuropathy symptoms (according to TSS scale) by 28%.

2. Glutathione has the ability to reverse diabetic neuropathy in terms of loss of sensation, reducing neurological symptoms by NDS scale by 28.6%.

3. Changes by NSS in the experimental group was 28%.

THE ROLE OF INTERLEUKIN-6 GENE POLYMORPHISM IN ASSESSING THE DEVELOPMENT AND CLINICAL COURSE OF THE DISEASE IN PATIENTS WITH HCV-ASSOCIATED ARTHRITIS

SHUKUROVA F.N., KARIMOV M.SH.

Tashkent Medical Academy, Tashkent, Uzbekistan

Purpose of the study. To study the nature of the relationship between IL-6 genotypes and the development and progression of the clinical course of associated arthritis (HCVaA) with viral hepatitis C.

Material and methods. All examined patients were divided into 2 groups: group 1 – the main group – 52 patients with a positive response to HCV and observed associated arthritis, group 2 – the comparison group included 23 patients with chronic hepatitis C without associated arthritis. A study was conducted on 52 patients (mean age 38.54 ± 6.00 years) with a diagnosis of chronic viral hepatitis C. The material for studying the frequency of occurrence of single nucle-

otide substitution C-174G of the IL6 gene was samples of genomic DNA obtained from peripheral blood leukocytes of patients (52 patients with HCVaA of the main group and 82 of the control group) using a kit for RNA/DNA extraction from clinical material. «Amply Prime-RIBO-prep». To detect polymorphism of the IL6 gene, a polymerase chain reaction (PCR) was performed with a reagent kit for determining the C-174G polymorphism of the IL6 gene. Studies of the C-174G polymorphism of the IL6 gene were carried out in the laboratory of the Department of Molecular Medicine and Cell Technologies of the Research Institute of Hematology and Blood Transfusion.

СОДЕРЖАНИЕ

THE CLINICAL COURSE OF CORONARY HEART DISEASE AFTER A CORONAVIRUS INFECTION «COVID-19» Akhmentayeva D.A., Lissovenko O.I., Rakhmankul D.Zh., Sovetkanova P.E., Mayufi A.M., Dursunov S.D., Aliakbarov E.A.	3
GASTROPATHIES IN RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF HELICOBACTER PYLORI VIRULENCE Azadayeva K.E., Tukhtaeva N.Kh., Rahmatullayeva G.K.	3
INFLUENCE OF CARDIAC PATHOLOGY ON THE CURRENT AND OUTCOMES OF PREGNANCY AND BIRTH Babadjanova G.S., Uzakova M.K., Eshonkhodjaeva D.D.	4
PSYCHOLOGICAL ASPECTS OF COMMITMENT TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS Jamalov A.Sh., Ahmedova N.A.	4
VARIOUS DESTRUCTIVE PROCESS IN JOINTS OF PATIENTS WITH REACTIVE ARTHRITIS Khalmetova F.I., Sadikova G.S.	5
DEVELOPMENT OF CHRONIC GASTRODUODENAL PATHOLOGY IN HELICOBACTERIOSIS Khudayberganova N.Kh., Akhmedova I.M.	5
ANTIHYPERTENSIVE EFFECTIVENESS OF A TWO-COMPONENT FIXED COMBINATION OF ANGIOTENSIN II RECEPTOR BLOCKER WITH CALCIUM CHANNEL BLOCKER AND ITS EFFECT ON THE PARAMETERS OF 24-HOUR BLOOD PRESSURE MONITORING IN PATIENTS WITH ARTERIAL HYPERTENSION WITH OBESITY Koval S.M., Penkova M. Yu., Mysnychenko O.V.	6
PECULIARITIES OF THE COURSE OF ARTERIAL HYPERTENSION IN PATIENTS AFTER COVID-19 Koval S.M., Rieznik L.A., Penkova M. Yu., Mysnychenko O.V.	7
RELATIONSHIP OF THE BLOOD LEVELS OF INSULIN-LIKE GROWTH FACTOR-1 WITH THE CHARACTER OF LEFT VENTRICLE REMODELING IN PATIENTS WITH ARTERIAL HYPERTENSION, WHICH OCCURS ON THE BACKGROUND OF OBESITY Koval S.M., Starchenko T.G., Reznik L.A., Miloslavsky D.K., Lytvynova O.M.	8
FEATURES OF NUTRITION CHARACTER AND MODIFY CARDIOVASCULAR RISK FACTORS IN HYPER ENSE PATIENTS WITH OBESITY Miloslavsky D.K., Snigurksal. O., Penkova M. Yu., Rieznik L.A., Starchenko T.G., Babijchuk L.V.	8
COVID-19 CAN AFFECT DISEASE ACTIVITY OF THE PATIENTS WITH ANKYLOSING SPONDYLOARTHRITIS Mirakhmedova Kh.T., Saidrasulova G.B.	9
EFFECT OF REBAGIT ON GASTRIC MUCOSA IN PATIENTS WITH NSAID GASTROPATHY Musaeva L.J., Akbarova D.S., Pulatova N.I., Saifeva N.H.	10
IMPACTS OF SYSTEMIC SCLEROSIS ON THE INTESTINAL TRACT AND LARGE INTESTINE OBSTRUCTION Po'latova N. O', Abdurazzakova D.S.	10
THERAPEUTIC EFFECTS OF GLUTATHIONE ON DIABETIC NEUROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS Shagzatova B.KH, Artikova D.M, Artikova Sh.A.	11
THE ROLE OF INTERLEUKIN-6 GENE POLYMORPHISM IN ASSESSING THE DEVELOPMENT AND CLINICAL COURSE OF THE DISEASE IN PATIENTS WITH HCV-ASSOCIATED ARTHRITIS Shukurova F.N., Karimov M.Sh.	11
INCREASING CONTROL OF ARTERIAL HYPERTENSION BY USING HOME BLOOD PRESSURE MONITORING IN HYPERTENSIVE PATIENTS WITH OBESITY Snihurstskaya I.O., Koval S.M., Miloslavsky D.K.	12
FUNCTIONAL STATE OF THE KIDNEYS IN ELDERLY PATIENTS AFTER MYOCARDIAL INFARCTION Talipov R.M., Nurmetov Kh.T., Khudayberganova N.Kh.	13
ASSESSMENT OF COMPARATIVE ANALYSIS OF THE COURSE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN MIDDLE- AGED AND ELDERLY PATIENTS WHO SUFFER COVID-19 THROUGH ULTRASOUND ELASTOMETRY (VIA FIBROSCAN) Zokirov V.Z., Yuldasheva D.X.	13
EXPERIENCE OF USING MONTIGET IN PATIENTS WITH BRONCHIAL ASTHMA OF MODERATE TO SEVERE COURSE Zufarov P.S., Saidova Sh.A., Akbarova D.S., Musaeva L.J., Pulatova D.B., Abdumajidova N.H.	14
COVID 19 VA MIOKARD INFARKTI BILAN XASTALANGAN BEMORLARNING AMBULATOR KUZATUVI SHAROITIDAGI LABORATOR TEKSHIRUVLAR VA XAVF OMILLARINING TAXLILI Abdukadirova N.M., Tulaboyeva G.M., Tolipova Yu.Sh., Muminov S.Dj., Saidov X.X.	14
COVID 19 BILAN ZARARLANGAN BEMORLARDA MIOKARD INFARKTINING O'ZIGA XOS XUSUSIYATLARI Abdukadirova N.M., Tulaboyeva G.M., Sagatova X.M., Tolipova Yu.Sh., Muminov S.Dj.	15
REVMATOID ARTRIT KASALLIGIDA NYAQDV INDUTSIRLANGAN GASTROPATIYALI BEMORLARNING XUSUSIYATLARI Abdurazzakova D.S., Matchanov S.X., Tashpulatova M.M., Aliyeva K.K.	16
TURLI GENEZLI PARENXIMATOZ GEMORRAGIK INSULT KASALLIGINING O'ZIGA XOS KECHISHI Akbaraliyeva S.U., Raximbayeva G.S.	16
SURUNKALI BUYRAK KASALLIGIDA RENAL KAMQONLIKNI REGIONAL KECHISH XUSUSIYATLARI Aybergenova X.Sh., Umarova Z.F., Jabborov O.O.	17
REAKTIV ARTRITLI BEMORLARDA GASTRODUODENAL SOHASIDA H. PYLORI MAVJUDLIGI VA UNI DAVOLASH TURIGA BOG'LIQLIGI Azadayeva K.E., Tuxtayeva N.X., Abzalova D.A.	17
O'TKIR NAFAS YETISHMOVCHILIGI BILAN ASORATLANGAN YANGI KORONAVIRUS INFEKSIYASI COVID-19 DA NOINVAZIV O'PKA VENTILYATSIIYASI Boltayev E.B.	18